中文題目:胰臟神經內分泌瘤肝脾轉移患者呈現高血胺昏迷一例報告 英文題目:A rare presentation of hyperammonemia encephalopathy in a patient with pancreatic neuroendocrine tumor with liver/spleen metastases - a case report

作 者:陳維常 陳書昱 林哲斌²

服務單位:1台北國泰醫院內科 2台北國泰醫院血液腫瘤科

Introduction:

We report here a rare presentation of hyperammonemia encephalopathy in a patient of pancreatic neuroendocrine tumor with liver and spleen metastases, whose liver function is still in Child-Pough class A . The developing of hyperammonemia is probably due to tumor porta-systemic shunting instead of disease progression. this rare presentation should be kept in mind in treating the neuroendocrine tumors.

Case report:

A 63 years old female came to our ER due to chronic diarrhea for 2 months and body weight loss 4 kg. The admission examination unveil she is a victim of pancreatic neuroendocrine tumor gr 2, stage IV, with liver and spleen metastases. The neuroendocrine tumor is secretory type, with severe symptoms of diarrhea (>10 times/day), urine 5-HIAA 4.18mg/day (2-8 mg/day), chromogranin 285.9 ng/mL (19.4-98.1 ng/mL); but her liver function is good: GOT 23 IU/L, GPT 23 IU/L, T.Bilirubin 0.4mg/dl, albumin 3.6 gm/dL, PT 9.9 sec, INR 0.92, HBsAg (-), Anti-HBs (+), anti-HCV (-); while ammonia is the only data abnormally elevated: 46 umol/L (9-33). Because there were no encephalopathy and no ascites, her Child-Pough score is 5, class A. Her other lab data are normal, including WBC 5.74 x109/L, Hb 12.8 g/dL, Platelets 163 x109/L, normal renal function, and normal stool & urine examinations.

After confirmation of the diagnosis , we give her everolimus 10 mg/day. On day 24 of using everolimus , she was sent to our ER due to nausea vomiting , and consciousness disturbance. Laboratory data revealed glucose 205 mg/dl , Ca14.3 mg/dl , K 3.4 mmol/L, Na137 mmol/L , GOT/GPT 42/37 IU/L , Albumin 4.3 mg/dL, T. Bilirubin 0.8 mg/dL , BUN/Cr 39/1.31 mg/dL, ammonia was checked and was elevated up to 103 mmol/L. The Glasgow coma scale was E3V4M5.

Under the impression of hyperammonemia encephalopathy, we treat her with lactulose, and in the meantime start the treatment of octreotide (30 mg).

Her ammonia recovered soon(fig.3), coma scale returned to E4V5M6 and the diarrhea also completely recovered to once/day one week later.

The patient now receiving everolimus and octreotide therapy, the clinical condition is stable now.

Discussion:

The hyperammonemia or hyperammonemia encephalopathy is a rare event in neuroendocrine tumor patients, especially when the patient had no cirrhosis of liver. Several case reports in literature had attributed the cause to portal-systemic shunt (1,2). In our case, This patient had multiple small liver metastases, but the spleen hilum vessels and gastric vessels are heavily engorged (fig.1,2), indicating there might be a porta-systemic shunt, causing hyperammonemia. The patient later developed encephalopathy, we figure that the target therapy drug work out slowly, and the drug might causing patient loss appetites, dehydration and slowly developed the encephalopathy as ammonia gradually elevated. Afterward, the combination therapy worked, the tumor being controlled, ammonia level returns normal.



Fig 1. Splenic hila tumor, vessels

Fig 2 Engorged vessels



Fig 3 Ammonia changes

References:

- 1. Hyperammmonemic encephalopathy in diffuse liver metastases , is this the end stage? J Gastro. 2012, 12:09
- 2. Reversing hyperammonemia in neuroendocrine tumor. J Clin Gastro 2010,44:186